Shi-Yi Wang, MD, PhD
Senior Research Scientist in EpidemiologyDownloadHi-Res Photo
Cards
Contact Info
About
Copy Link
Titles
Senior Research Scientist in Epidemiology
Biography
Dr. Wang is an Associate Professor at the Yale School of Public Health, faculty member of Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, and faculty member of Public Health Modeling Concentration, Yale School of Public Health. His primary interests focus on outcomes research and decision science. He is interested in combining systematic literature reviews, secondary data analyses, and simulation modeling to examine issues that are critical to clinicians and policy makers’ decision making. He has been working on several breast cancer projects, including an evaluation of preoperative breast MRI, development of an individualized decision aid to help radiotherapy decision-making, and assessment of sentinel lymph node biopsy for patients with ductal carcinoma in situ. He is also evaluating end-of-life care quality. He has served as the primary investigator or co-investigator in several projects (funded by Yale Cancer Center, AHRQ, NCI, ACS, and PCORI).
Last Updated on April 07, 2025.
Appointments
Chronic Disease Epidemiology
Senior Research ScientistPrimaryChronic Disease Epidemiology
LecturerSecondary
Other Departments & Organizations
Education & Training
- PhD
- University of Minnesota (2012)
- MD
- Taipei Medical College (1992)
Research
Copy Link
Overview
Medical Research Interests
Breast Neoplasms; Terminal Care
Public Health Interests
Aging; Cancer; End-of-life Care; Global Health; Health Care Quality, Efficiency; Modeling
ORCID
0000-0002-3294-5784
Research at a Glance
Yale Co-Authors
Frequent collaborators of Shi-Yi Wang's published research.
Publications Timeline
A big-picture view of Shi-Yi Wang's research output by year.
Research Interests
Research topics Shi-Yi Wang is interested in exploring.
Cary P Gross, MD
Xiaomei Ma, PhD
Rong Wang, PhD
Michaela Dinan, PhD
Natalia Neparidze, MD
Michael S. Leapman, MD, MHS
114Publications
4,021Citations
Breast Neoplasms
Terminal Care
Publications
2026
Matched targeted therapy use after broad genomic profiling in advanced Non-Small cell lung cancer
Wang X, Long J, Rothen J, Aremu A, Huang S, Soulos P, Robinson T, Presley C, Goldberg S, Mamtani R, Wang S, Ma S, Dinan M, Gross C. Matched targeted therapy use after broad genomic profiling in advanced Non-Small cell lung cancer. Journal Of The National Cancer Institute 2026, djag310. PMID: 42679379, DOI: 10.1093/jnci/djag310.Peer-Reviewed Original ResearchAltmetricReal‐World Efficacy and Safety of Standard‐of‐Care Chimeric Antigen Receptor T‐Cell (CART) and Bispecific T‐Cell Engager (TCE) Therapies in Relapsed/Refractory Multiple Myeloma (RRMM)
Theprungsirikul P, Wang R, Chang S, Bar N, Browning S, Parker T, Wang S, Neparidze N. Real‐World Efficacy and Safety of Standard‐of‐Care Chimeric Antigen Receptor T‐Cell (CART) and Bispecific T‐Cell Engager (TCE) Therapies in Relapsed/Refractory Multiple Myeloma (RRMM). European Journal Of Haematology 2026 PMID: 42676230, DOI: 10.1111/ejh.70304.Peer-Reviewed Original ResearchAltmetricTreatment patterns for patients with initial diagnosis of smoldering multiple myeloma in the United States: a SEER-Medicare analysis.
Wang R, Hsu S, Neparidze N, Schoen M, Chang S, Wang S. Treatment patterns for patients with initial diagnosis of smoldering multiple myeloma in the United States: a SEER-Medicare analysis. Haematologica 2026 PMID: 42459117, DOI: 10.3324/haematol.2026.300684.Peer-Reviewed Original ResearchAltmetricIncidence of depression in patients with psoriasis and psoriatic arthritis treated with biologic therapy: Protocol for a systematic review and meta-analysis
Sirotich E, Lowry W, Wang S, Jurgens M, Cohen J. Incidence of depression in patients with psoriasis and psoriatic arthritis treated with biologic therapy: Protocol for a systematic review and meta-analysis. PLOS ONE 2026, 21: e0351646. PMID: 42371910, PMCID: PMC13313330, DOI: 10.1371/journal.pone.0351646.Peer-Reviewed Original ResearchPotential Benefits and Harms of Screening Strategies for Monoclonal Gammopathy of Undetermined Significance in the US: A Simulation Study
Ahmad I, Wang R, Neparidze N, Lange J, Wang S. Potential Benefits and Harms of Screening Strategies for Monoclonal Gammopathy of Undetermined Significance in the US: A Simulation Study. Clinical Lymphoma Myeloma & Leukemia 2026, 26: e1035-e1042.e1. PMID: 42392944, DOI: 10.1016/j.clml.2026.06.001.Peer-Reviewed Original ResearchImmunomodulatory Agent Adherence Trajectories and Survival Among Older Patients With Multiple Myeloma.
Wang R, Ji M, Neparidze N, Ma X, Chang S, Wang S. Immunomodulatory Agent Adherence Trajectories and Survival Among Older Patients With Multiple Myeloma. JCO Oncology Practice 2026, op2500615. PMID: 42081788, DOI: 10.1200/op-25-00615.Peer-Reviewed Original ResearchAltmetricTreatment Patterns Across Lines of Therapy for Advanced Non‐Small Cell Lung Cancer in the United States
Lee D, Li Y, Yang S, Chiang A, Soulos P, Gross C, Wang S. Treatment Patterns Across Lines of Therapy for Advanced Non‐Small Cell Lung Cancer in the United States. Cancer Medicine 2026, 15: e71736. PMID: 42007970, PMCID: PMC13094514, DOI: 10.1002/cam4.71736.Peer-Reviewed Original ResearchAltmetricQIM26-284: Practice-Level Variation in ECOG Performance Status Documentation in Advanced Non–Small Cell Lung Cancer
Li Y, Wang S, Zhang Y, Yang S, Lee D, Soulos P, Wang X, Gross C, Chiang A. QIM26-284: Practice-Level Variation in ECOG Performance Status Documentation in Advanced Non–Small Cell Lung Cancer. Journal Of The National Comprehensive Cancer Network 2026, 24 DOI: 10.6004/jnccn.2025.7441.Peer-Reviewed Original ResearchQuantifying the contribution of modifiable risk factors for progression of MGUS to multiple myeloma in a Veteran population
Wang M, Sigel B, Liu L, Huber J, Ji M, Schoen M, Sanfilippo K, Thomas T, Colditz G, Hsu S, Wang S, Chang S. Quantifying the contribution of modifiable risk factors for progression of MGUS to multiple myeloma in a Veteran population. International Journal Of Cancer 2026, 159: 618-628. PMID: 41813601, PMCID: PMC13004480, DOI: 10.1002/ijc.70412.Peer-Reviewed Original ResearchAltmetricThe association between body fatness and prevalent MGUS in the U.S. general population
Ji M, Huber J, Wang M, Lan T, Colditz G, Wang S, Chang S. The association between body fatness and prevalent MGUS in the U.S. general population. Cancer Epidemiology 2026, 101: 103021. PMID: 41702266, PMCID: PMC13081065, DOI: 10.1016/j.canep.2026.103021.Peer-Reviewed Original ResearchCitations
Academic Achievements & Community Involvement
Copy Link
Honors
honor The Population Science Research Prize
01/31/2017Other AwardYale Cancer CenterDetailsUnited Stateshonor The Distinguished Student Mentor Award
06/30/2016Other AwardYale School of Public HealthDetailsUnited States
News
Copy Link
News
- May 06, 2025
Genetic Test Underused in Cancer Care
- August 07, 2023
Screening Mammograms Carry Risks for Older Women, Study Finds
- May 05, 2023
Becca Levy and the Fight Against Ageism
- March 05, 2023
Improving Care of Patients Receiving Advanced Cancer Treatment
Get In Touch
Copy Link
Contacts
Email
Academic Office Number
Locations
60 College Street
Academic Office
Ste 432
New Haven, CT 06510